Skip Navigation

European Journal of Heart Failure 2003 5(1):95-99; doi:10.1016/S1388-9842(02)00249-0
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Coletta, A.P.
Right arrow Articles by Cleland, J.G.F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coletta, A.P.
Right arrow Articles by Cleland, J.G.F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2002 European Society of Cardiology

Clinical trials update from the American Heart Association meeting: PROSPER, DIAL, home care monitoring trials, immune modulation therapy, COMPANION and anaemia in heart failure

A.P. Coletta*, N. Nikitin, A.L. Clark and J.G.F. Cleland

Department of Academic Cardiology, Castle Hill Hospital Cottingham, Kingston upon Hull HU16 5JQ, UK

* Corresponding author. Tel.: +44-1482-622613; fax: +44-1482-624085 E-mail address: a.p.coletta{at}hull.ac.uk


  Abstract

This article continues a series of reports on research developments of particular interest to those involved in the management of patients with heart failure. Summaries of the following trials, reported at the 75th Scientific Sessions of the American Heart Association held in Chicago, Illinois between 17th and 20th November 2002 are included: PROSPER; DIAL; home care monitoring trials; immune modulation therapy; COMPANION; and anaemia in heart failure.

Key Words: PROSPER • DIAL • COMPANION • Heart failure • Telemonitoring • Anaemia

Received November 28, 2002; Accepted December 4, 2002


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
L. G. Olsson, K. Swedberg, A. L. Clark, K. K. Witte, and J. G.F. Cleland
Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review
Eur. Heart J., April 2, 2005; 26(8): 778 - 793.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
S. Capomolla, G. Pinna, M. T. La Rovere, R. Maestri, M. Ceresa, M. Ferrari, O. Febo, A. Caporotondi, G. Guazzotti, F. Lenta, et al.
Heart failure case disease management program: a pilot study of home telemonitoring versus usual care
Eur. Heart J. Suppl., November 1, 2004; 6(suppl_F): F91 - F98.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
A. A. Louis, T. Turner, M. Gretton, A. Baksh, and J. G.F. Cleland
A systematic review of telemonitoring for the management of heart failure
Eur J Heart Fail, October 1, 2003; 5(5): 583 - 590.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
G. Boriani, M. Biffi, C. Martignani, C. Camanini, F. Grigioni, C. Rapezzi, and A. Branzi
Cardioverter-defibrillators after MADIT-II: the balance between weight of evidence and treatment costs
Eur J Heart Fail, August 1, 2003; 5(4): 419 - 425.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
J. G.F. Cleland, A. P. Coletta, N. Nikitin, A. Louis, and A. Clark
Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans
Eur J Heart Fail, June 1, 2003; 5(3): 391 - 398.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.